Minnesota Living with Heart Failure Questionnaire

Abstract

The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is one of the most widely used and psychometrically evaluated patient-reported outcome measures (PROMs) designed to assess health-related quality of life (HRQoL) in individuals diagnosed with heart failure. Developed by Thomas S. Rector and colleagues in 1987 at the University of Minnesota, the MLHFQ measures the multidimensional burden imposed by cardiac dysfunction across physical, emotional, socioeconomic, and social domains of everyday living. The questionnaire comprises 21 items that ask respondents to rate how much their heart failure has prevented them from living as they wanted during the past month. Each item is scored on a six-point Likert-type scale ranging from 0 (“No”) to 5 (“Very much”), yielding a total composite score between 0 and 105, where higher scores reflect poorer HRQoL.

Psychometrically, the MLHFQ demonstrates a well-established two-factor internal structure consisting of a Physical dimension (8 items, score range 0–40) and an Emotional dimension (5 items, score range 0–25), alongside eight non-dimensionalized items addressing socioeconomic, dietary, and treatment-related challenges that contribute directly to the total score. The instrument exhibits excellent internal consistency, with Cronbach’s alpha coefficients regularly exceeding .85 for the subscales and .90 for the total score, as well as robust test-retest reliability (intraclass correlation coefficients typically > .80). It shows pronounced construct, convergent, and discriminant validity, demonstrating strong associations with New York Heart Association (NYHA) functional class, exercise capacity (e.g., six-minute walk test), and depressive symptomatology. Moreover, its documented sensitivity to therapeutic interventions and defined minimally clinically important difference (MCID) make it an essential endpoint in clinical trials and routine cardiology practice worldwide.

Keywords

Minnesota Living with Heart Failure Questionnaire, MLHFQ, heart failure, health-related quality of life, patient-reported outcome measures, psychometrics, physical functioning, emotional well-being, cardiac rehabilitation, disease burden

Authors

The Minnesota Living with Heart Failure Questionnaire was developed by:

• Thomas S. Rector, PhD — Department of Medicine and Department of Epidemiology, University of Minnesota, Minneapolis, Minnesota, United States.
• Jay N. Cohn, MD — Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, United States.

Subsequent psychometric adaptations and linguistic validations have been conducted globally, including the Dutch validation by A. A. Wijbenga and colleagues (1998) at Erasmus University Medical Center and University Hospital Rotterdam.

Purpose

Heart failure is a complex clinical syndrome characterized by impaired ventricular filling or ejection capacity, leading to fatigue, dyspnea, peripheral edema, and exercise intolerance. While traditional physiological biomarkers (e.g., left ventricular ejection fraction, B-type natriuretic peptide) quantify disease severity, they correlate weakly with a patient’s functional capacity and subjective sense of well-being. The primary purpose of the MLHFQ is to bridge this clinical gap by providing a standardized, disease-specific metric that captures how heart failure and its treatment regimens affect a patient’s day-to-day functional and psychological reality.

The instrument was designed with two major applications in mind:

• Clinical Research and Pharmacological Trials: Serving as an evaluative end-point to detect changes in quality of life following therapeutic interventions, such as beta-blocker therapy, ACE-inhibitors, cardiac resynchronization therapy (CRT), structured exercise training, and disease management programs. The scale has demonstrated clinical utility across landmark cardiovascular randomized trials.
• Routine Clinical Monitoring: Assisting multidisciplinary cardiology care teams, advanced practice nurses, and cardiologists in tracking symptom escalation, determining treatment tolerability, recognizing the onset of reactive psychological distress, and guiding patient-centered care plans.

By measuring the specific impediments caused by heart failure across a distinct 4-week recall window, the MLHFQ isolates disease-attributed disability from non-specific age-related impairments or unrelated medical comorbidities.

Psychological Construct

The MLHFQ operationalizes the overarching construct of disease-specific Health-Related Quality of Life (HRQoL) in heart failure. In accordance with contemporary health measurement frameworks, HRQoL is conceptualized as a multidimensional construct encompassing the biological, functional, and psychological manifestations of disease as perceived directly by the patient. The questionnaire structures this construct into two validated subscales and additional non-dimensionalized items:

1. Physical Dimension (8 Items)

The Physical subscale assesses limitations in mobility, physiological stamina, and self-care imposed by hallmark cardiac symptoms, including dyspnea, fatigue, and fluid retention. The items evaluate:

• The need to sit or lie down to rest during the day (Item 2)
• Difficulty walking or climbing stairs (Item 3)
• Impairment in domestic chores and yard work (Item 4)
• Mobility restrictions away from the home environment (Item 5)
• Shortness of breath interfering with activities (Item 12)
• Tiredness, fatigue, or low energy reserves (Item 13)
• Hospitalization requirements (Item 14)
• Medical care costs associated with physical management (Item 15)

Higher scores in this domain reflect progressive somatic debility, directly mirroring worsening functional stages of cardiac illness.

2. Emotional Dimension (5 Items)

The Emotional subscale addresses the affective, cognitive, and interpersonal toll of surviving with a chronic, progressive, and life-limiting cardiac condition. Heart failure often introduces pervasive uncertainty, fear of sudden decompensation, and loss of functional autonomy. This dimension assesses:

• Feeling like a burden to friends or family (Item 17)
• Experiencing a loss of self-control over one’s life trajectory (Item 18)
• Persistent worry or anxiety regarding disease outcomes (Item 19)
• Impaired cognitive concentration or memory problems (Item 20)
• Feelings of depression and despondency (Item 21)

3. Additional Life-Impact Items (8 Items)

Eight items evaluate specific functional and social domains that do not load cleanly onto a single secondary factor but contribute essentially to the global HRQoL composite. These items capture ankle swelling (Item 1), sleep architecture disruptions (Item 6), interpersonal relations with family/friends (Item 7), vocational and occupational productivity (Item 8), recreational pastimes and hobbies (Item 9), sexual intimacy and functioning (Item 10), dietary restrictions and loss of dietary enjoyment (Item 11), and pharmacological side effects (Item 16).

Theoretical Framework

The theoretical architecture of the MLHFQ is grounded in the biopsychosocial model of health pioneered by George Engel, alongside classical models of disease impact such as the Wilson and Cleary Model of Patient Outcomes (1995). Under this paradigm, clinical assessment cannot terminate at the level of biological or physiological variables (such as left ventricular remodeling or hemodynamic parameters). Instead, a causal continuum links biological impairment to symptom status, functioning, general health perceptions, and ultimately subjective quality of life.

Rector and Cohn formulated the scale around the hypothesis that heart failure exerts an adverse effect on quality of life through a progressive mechanism:

1. Pathophysiological Impairment: Compromised cardiac output and elevated neurohormonal activation produce physiological limitations.
2. Symptom Manifestation: The patient experiences cardinal symptoms including dyspnea on exertion, orthopnea, nocturnal paroxysmal dyspnea, and peripheral edema.
3. Functional Limitation: Symptoms force behavioral modifications, requiring frequent rest, restricting occupational duties, and preventing leisure participation.
4. Psychological & Social Distress: Sustained physical restriction causes affective morbidity, such as reactive depression, perceived loss of autonomy, and perceived social burden.

By framing each questionnaire stem around whether the heart failure “prevented you from living as you wanted,” the instrument directly captures the discrepancy between an individual’s personal aspirations and their actual functional reality—the operational definition of reduced quality of life.

Validity

The psychometric validity of the MLHFQ has been substantiated across hundreds of validation studies in diverse clinical cohorts:

Construct and Convergent Validity

The MLHFQ demonstrates strong convergent validity with established measures of physical functioning and clinical severity. Total and Physical subscale scores correlate significantly with NYHA functional class ($r = .50$ to $.65, p < .001$), with stepwise increases in score observed from Class I through Class IV. Moderate-to-strong correlations are reported between the Physical subscale and objective functional capacity, including the Six-Minute Walk Test (6MWT) ($r = -.40$ to $-.58$) and peak oxygen uptake ($ ext{VO}_2$ peak, $r = -.45$). The Emotional subscale demonstrates robust convergent associations with validated psychiatric screeners, correlating strongly with the Beck Depression Inventory ($r = .62$ to $.70$) and the Hospital Anxiety and Depression Scale (HADS).

Discriminant Validity

Discriminant validity is supported by the tool’s ability to differentiate between clinically stable patients and those undergoing acute decompensation or hospital readmission. The scale distinguishes effectively between heart failure patients with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF) when stratified by functional severity, while showing low correlations ($r < .20$) with non-cardiac demographic variables such as chronological age and biological sex.

Predictive Validity and Responsiveness

The MLHFQ possesses established prognostic utility. Elevated baseline total scores and deteriorating scores over time independently predict heart failure hospitalization, cardiac transplantation referral, and all-cause cardiovascular mortality. The questionnaire exhibits high responsiveness to change (effect sizes > 0.50 following pharmacological optimization, cardiac resynchronization therapy, or structured exercise rehabilitation). The consensus minimally clinically important difference (MCID) for the total score is established as 5 points; a decrease of 5 points represents clinically meaningful improvement, whereas a 5-point increase indicates meaningful clinical deterioration.

Reliability

Extensive psychometric investigations have affirmed the high reliability of the MLHFQ across diverse clinical settings:

Internal Consistency

Across validation studies spanning North America, Europe, Asia, and South America, the internal consistency of the MLHFQ consistently meets or exceeds standard thresholds for clinical metrics:

• Total Score: Cronbach’s $\alpha$ routinely ranges between .88 and .94.
• Physical Dimension: Cronbach’s $\alpha$ ranges between .85 and .90.
• Emotional Dimension: Cronbach’s $\alpha$ ranges between .75 and .86.

Item-total correlations for individual items reliably exceed the recommended .40 cutoff, confirming that individual questions contribute substantially to their designated constructs without excessive collinear redundancy.

Test-Retest Reliability

In clinically stable heart failure outpatients reassessed across intervals ranging from 1 to 4 weeks, the MLHFQ demonstrates high reproducibility:

• Total score intraclass correlation coefficients (ICC) or Pearson $r$ range from .84 to .92.
• Physical dimension ICCs range from .81 to .89.
• Emotional dimension ICCs range from .78 to .85.

Standard error of measurement (SEM) analyses show low measurement noise, ensuring that score shifts reflect genuine alterations in health status rather than psychometric instability.

Factor Analysis

The internal dimensionality of the MLHFQ has been rigorously examined using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA):

Original Two-Factor Structure

Rector and colleagues initially identified two primary underlying factors that accounted for the majority of the common variance:

• Physical Factor: Comprising items 2, 3, 4, 5, 12, 13, 14, and 15, with factor loadings typically ranging between .55 and .84.
• Emotional Factor: Comprising items 17, 18, 19, 20, and 21, with factor loadings typically ranging between .50 and .81.

The remaining 8 items (1, 6, 7, 8, 9, 10, 11, and 16) demonstrated diffuse cross-loadings across social, economic, and somatic components, leading the scale developers to exclude them from formal subscale sub-scores while retaining them within the 21-item total score calculation.

Confirmatory Factor Modeling

Subsequent structural equation modeling across international cohorts has tested alternative models, including unidimensional, correlated two-factor, three-factor (adding a “Socioeconomic” or “Social” dimension), and bifactor models. Confirmatory analyses indicate that a bifactor model (featuring a general HRQoL factor alongside distinct Physical and Emotional specific factors) or a correlated two-factor model provides an acceptable fit to the empirical data:

• Comparative Fit Index (CFI) > .92
• Tucker-Lewis Index (TLI) > .90
• Root Mean Square Error of Approximation (RMSEA) < .065
• Standardized Root Mean Square Residual (SRMR) < .060

These findings substantiate the practice of reporting both the Physical and Emotional subscales alongside the overarching Total composite score.

Instrument / Measurement Tool

• Instrument Name: Minnesota Living with Heart Failure Questionnaire (MLHFQ)
• Original Authors: Thomas S. Rector, PhD & Jay N. Cohn, MD (1987)
• Assessment Type: Patient-Reported Outcome Measure (PROM) / Disease-specific self-report health questionnaire
• Target Population: Adult and elderly patients diagnosed with heart failure (NYHA functional classes I–IV; both HFrEF and HFpEF)
• Administration Format: Paper-and-pencil questionnaire, electronic PRO (ePRO), or clinician/nurse-administered interview
• Administration Time: Approximately 5 to 10 minutes
• Number of Items: 21 items
• Recall Period: The past month (4 weeks)
• Response Format: 6-point Likert-type scale:
  • 0 = No
  • 1 = Very little
  • 2 = A little
  • 3 = A moderate amount
  • 4 = Quite a bit
  • 5 = Very much
• Scoring Structure:
  • Total Score: Sum of all 21 items. Score range: 0 to 105.
  • Physical Dimension: Sum of 8 items (Items 2, 3, 4, 5, 12, 13, 14, 15). Score range: 0 to 40.
  • Emotional Dimension: Sum of 5 items (Items 17, 18, 19, 20, 21). Score range: 0 to 25.
  • Additional Items: Items 1, 6, 7, 8, 9, 10, 11, and 16 contribute directly to the total score but are not aggregated into a distinct subscale.
  • Interpretation: Higher scores reflect greater impairment and poorer health-related quality of life. Lower scores indicate minimal perceived impact of heart failure. A change of 5 points represents the Minimally Clinically Important Difference (MCID).

Permissions & Fee and Test Year

The Minnesota Living with Heart Failure Questionnaire was first introduced in 1987 by Thomas S. Rector and Jay N. Cohn. The MLHFQ is copyrighted by the Regents of the University of Minnesota.

While the instrument has been translated into over 30 languages and is widely utilized in clinical practice and clinical research worldwide, administrative permissions must be secured prior to formal use:

• Academic and Non-Funded Clinical Use: Academic researchers, students, and non-commercial healthcare providers can typically obtain permission for clinical and research purposes through formal registration with the University of Minnesota’s Office for Technology Commercialization. Modest administrative or translation licensing fees may apply depending on the scope of the study.
• Commercial and Industry-Sponsored Clinical Trials: For-profit pharmaceutical trials, device evaluations, and commercial entities must execute a commercial licensing agreement and pay applicable licensing fees administered by the University of Minnesota.
• Inquiries and Licensing: Permissions and official translations can be requested through the University of Minnesota Technology Commercialization Office.

References

Rector, T. S., Kubo, S. H., & Cohn, J. N. (1987). Patients’ self-assessment of their congestive heart failure. Part 2: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Failure, 3, 198–209.

Rector, T. S., & Cohn, J. N. (1992). Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. American Heart Journal, 124(4), 1017–1025. https://doi.org/10.1016/0002-8703(92)90986-6

Wijbenga, A. A., Kragten, J. A., & Van Den Brink, E. H. (1998). De ‘Minnesota Living with Heart Failure Questionnaire’: Een betrouwbare en valide maatstaf voor de kwaliteit van leven van patiënten met hartfalen [The Minnesota Living with Heart Failure Questionnaire: A reliable and valid instrument for assessing quality of life in patients with heart failure]. Nederlands Tijdschrift voor Geneeskunde, 142(38), 2100–2104.

Garin, O., Soriano, N., Ribera, A., Ferrer, M., Pont, A., Alonso, J., & Permanyer-Miralda, G. (2008). Validation of the Spanish version of the Minnesota Living with Heart Failure Questionnaire. Revista Española de Cardiología (English Edition), 61(3), 251–259. https://doi.org/10.1016/S1885-5857(08)60118-4

Behlouli, H., Feldman, D. E., Ducharme, A., Frenette, M., Giannetti, N., Grondin, F. R., Michel, C., Sheppard, R., & Pilote, L. (2009). Identifying the minimal clinically important difference in the Minnesota Living with Heart Failure Questionnaire. Cardiovascular Quality and Outcomes, 2(5), 450–456. https://doi.org/10.1161/CIRCOUTCOMES.109.854935

Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037

Items of the Scale